Azitra, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AZTR research report →
Price Chart
About the company
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases.
- CEO
- Francisco D. Salva
- IPO
- 2023
- Employees
- 13
- HQ
- Branford, CT, US
Get TickerSpark's AI analysis on AZTR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.36M
- P/E
- -0.09
- Fwd P/E
- 0.75
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.33
- EV/EBITDA
- 0.95
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -205.45%
- ROIC
- -159.45%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0-100.0%
- Op Income
- $-10,966,665
- Net Income
- $-10,955,370-22.2%
- EPS
- $-2.25+85.7%
- OCF Growth
- -10.2%
- FCF Growth
- -8.0%
- 52W High
- $1.40
- 52W Low
- $0.10
- 50D MA
- $0.15
- 200D MA
- $0.23
- Beta
- -1.18
- RSI (14)
- 40
- Avg Volume
- 11.73M
No earnings-call transcripts are available for AZTR yet.
- Free Float
- 94.9%
- Shares Outstanding
- 10.74M
- Float Shares
- 10.19M
of shares held by institutions
9 13F filers
Buy/sell ratio 4.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 16, 26 | Salva Francisco D. | other | 4,064,050 |
| Jun 16, 26 | Salva Francisco D. | other | 500 |
| Apr 20, 26 | Staskey Norm | other | 35,524 |
| Apr 20, 26 | Salva Francisco D. | other | 220,879 |
| Apr 20, 26 | Whitfill Travis | other | 64,300 |
| Mar 18, 26 | Salva Francisco D. | buy | 4,064,050 |
| Mar 18, 26 | Salva Francisco D. | buy | 4,064,050 |
| Mar 18, 26 | Salva Francisco D. | buy | 500 |
| Dec 19, 25 | Whitfill Travis | other | 23,724 |
| Dec 19, 25 | Salva Francisco D. | other | 59,309 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AZTR coverage
Recent articles, reports, and earnings notes.
No research on AZTR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AZTR report →Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates
prnewswire.com · Aug 12
Azitra, Inc. Announces Breakthough Repeat Dose and Anti-Wrinkle Ex Vivo Results for ATR-COSF Program, Demonstrating Increased Distribution and Elasticity
prnewswire.com · Jul 15
Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond
prnewswire.com · Jun 17
Azitra, Inc. to Present at 2026 BIO International Convention
prnewswire.com · Jun 16
Azitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting
prnewswire.com · Jun 4
Azitra Announces Intention to Adjourn Annual Meeting and Reconvene Annual Meeting
prnewswire.com · May 27
Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates
prnewswire.com · May 13
Azitra, Inc. Announces New U.S. Patent Protecting ATR-12 Program
prnewswire.com · May 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.